Skip to main content

News

Google Launches AI Tools To Accelerate Medical Research and Genomic Analysis

  • By John K. Waters
  • 05/20/2026

Key Takeaways

  • Google launched an AI suite to automate scientific workflows, validated by partnerships with 100+ institutions including Stanford and Imperial College London.
  • Hours to minutes — The tools compress complex bioinformatics and genomic workflows dramatically, powered by three prototypes covering hypothesis generation, parallel code testing, and medical literature summarization.
  • Daiichi Sankyo and Bayer Crop Science are already using the technology via Google Cloud to accelerate pharmaceutical and agricultural research.

Google on Wednesday introduced a new suite of artificial intelligence tools and experimental systems designed to automate core scientific workflows, a move that initial research suggests could accelerate medical discovery, genomic analysis, and epidemiological modeling.

The initiative, named "Gemini for Science," includes specialized capabilities tailored specifically for the life sciences and healthcare sectors. To validate the systems, Google has partnered with more than 100 academic and medical institutions. Early collaborations include a project with Stanford University focusing on liver fibrosis, a study with Imperial College London regarding antimicrobial resistance, and a multi-year research effort with The Francis Crick Institute.

A central component of the launch is a "Science Skills" package integrated into Google's agentic platform, Google Antigravity. The package aggregates data from more than 30 major life science databases and tools, including UniProt, the AlphaFold Protein Structure Database, the AlphaGenome API, and InterPro.

Google reported that its internal research teams used these tools to compress complex structural bioinformatics and genomic workflows from hours to minutes. In early testing, this acceleration allowed researchers to identify new data regarding the underlying mechanisms of a rare genetic disease caused by mutations in the AK2 gene.

The technology is also being deployed commercially within the pharmaceutical and biotechnology sectors through a private preview on Google Cloud. Japanese pharmaceutical firm Daiichi Sankyo is currently utilizing the tools to accelerate its research pipelines, while Bayer Crop Science is employing them to address agricultural and biological challenges.

The technological framework relies on three prototype tools available via Google Labs. The first, a hypothesis generation assistant built with a model called Co-Scientist, evaluates existing medical literature to generate, debate, and rank research ideas. The second, called Computational Discovery, uses Google's AlphaEvolve and Empirical Research Assistance (ERA) models to run thousands of code variations simultaneously, which the company says can help track complex public health trends such as solar forecasting and epidemiology. The third tool, Literature Insights, utilizes NotebookLM to summarize and cross-reference extensive bodies of medical text into searchable formats.

Coinciding with the announcement, research papers detailing the capabilities of Co-Scientist and ERA were published on Wednesday in the journal Nature.

Google noted that these new tools build upon its existing medical and biological AI implementations. These include AlphaFold, which researchers have used to study malaria vaccines; AlphaGenome, which helps identify the drivers of genetic diseases; and MedGemma, a model specifically tailored for healthcare applications.

About the Author

John K. Waters is the editor in chief of a number of Converge360.com sites, with a focus on high-end development, AI and future tech. He's been writing about cutting-edge technologies and culture of Silicon Valley for more than two decades, and he's written more than a dozen books. He also co-scripted the documentary film Silicon Valley: A 100 Year Renaissance, which aired on PBS.  He can be reached at [email protected].